Fresenius SE & Co. KGaA (ETR:FRE)
38.06
-1.65 (-4.16%)
Apr 4, 2025, 5:35 PM CET
Fresenius SE & Co. KGaA Revenue
In the year 2024, Fresenius SE & Co. KGaA had annual revenue of 21.83B EUR with 3.64% growth. Fresenius SE & Co. KGaA had revenue of 5.63B in the quarter ending December 31, 2024, with 4.72% growth.
Revenue
21.83B
Revenue Growth
+3.64%
P/S Ratio
1.02
Revenue / Employee
123.71K
Employees
176,486
Market Cap
22.37B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 21.83B | 766.00M | 3.64% |
Dec 31, 2023 | 21.07B | -465.00M | -2.16% |
Dec 31, 2022 | 21.53B | -15.99B | -42.61% |
Dec 31, 2021 | 37.52B | 1.24B | 3.43% |
Dec 31, 2020 | 36.28B | 868.00M | 2.45% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Merck KGaA | 21.16B |
Siemens Healthineers AG | 22.67B |
Bayer Aktiengesellschaft | 46.61B |
Fresenius Medical Care AG | 19.34B |
Sartorius Aktiengesellschaft | 3.38B |
Carl Zeiss Meditec AG | 2.08B |
Fielmann Group AG | 2.16B |
SCHOTT Pharma AG & Co. KGaA | 954.68M |
Fresenius SE & Co. KGaA News
- 3 days ago - EQS-PVR: Fresenius SE & Co. KGaA: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution - Wallstreet:Online
- 3 days ago - EQS-DD: Fresenius SE & Co. KGaA: Robert Möller, buy - Wallstreet:Online
- 3 days ago - EQS-DD: Fresenius SE & Co. KGaA: Pierluigi Antonelli, buy - Wallstreet:Online
- 3 days ago - EQS-DD: Fresenius SE & Co. KGaA: Sara Hennicken, buy - Wallstreet:Online
- 3 days ago - EQS-DD: Fresenius SE & Co. KGaA: Michael Sen, buy - Wallstreet:Online
- 9 days ago - Fresenius gets FDA approval for biosimilars of Amgen's bone-condition drugs - Seeking Alpha
- 19 days ago - Fresenius: Turnaround For Company, Stock Price - Seeking Alpha
- 4 weeks ago - Health Care Roundup: Market Talk - The Wall Street Journal